Satellos Bioscience Effectifs

Que fait Satellos Bioscience ? Satellos Bioscience Inc is a biotechnology company based in Toronto, Canada, operating within the health care sector. The company has a small team of three full-time employees. Satellos Bioscience went public through an IPO on December 1, 2006, and its stock trades under the ticker MSCL.TO with ISIN CA80401L8033. The company's primary focus is on developing therapeutics for degenerative muscle conditions, particularly through its MyoReGenX platform. This platform is designed to recreate the specialized muscle stem cell niche in vitro, enabling the mapping of pathways that modulate muscle repair and regeneration. The platform also supports the identification and confirmation of drug targets and the testing of drug candidates aimed at restoring impaired muscle stem cell repair mechanisms. Satellos Bioscience's lead program involves an oral, small molecule drug candidate intended as a disease-modifying treatment for Duchenne muscular dystrophy. The company also manages an iCo portfolio, which includes the Oral Amp B Delivery System, a patented oral transport technology, and Bertilimumab, a human monoclonal eotaxin antibody with potential applications in treating allergic and inflammatory conditions mediated by eotaxin-1. Satellos Bioscience maintains a website at https://satellos.com/ for further information. Satellos Bioscience est l'une des entreprises les plus populaires sur Eulerpool.